sanofi astrazeneca - Search News

News

Merck, Sanofi and AstraZeneca

CNBC on MSN · 3d

FDA approves Merck's RSV shot for infants, ramping up competition with Sanofi and AstraZeneca

Merck’s shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus.

Merck Wins FDA Nod for RSV Antibody, Tees Up Challenge to Sanofi, AstraZeneca

Merck’s Enflonsia will go up against Sanofi and AstraZeneca’s Beyfortus, which the partners plan to ship out early in the third quarter.

Seeking Alpha on MSN · 2d

Merck’s RSV shot for infants cleared in U.S., challenging Sanofi/Astra’s dominance

Merck (NYSE:MRK) has received FDA approval for Enflonsia, a prophylactic antibody therapy designed to protect infants from respiratory syncytial virus (RSV) in a market dominated by Beyfortus, a rival RSV preventive shot developed by Sanofi (NASDAQ:SNY) and AstraZeneca (NASDAQ:AZN).

Pharmalittle: We’re reading about a Merck shot for RSV, a lawsuit over an Arkansas PBM law, and more

Merck won FDA approval for a shot that protects against RSV, the most common cause of hospitalization among infants ...

1don MSN

Newly approved antibody could offer another option for protecting infants from RSV, a common infection that can be deadly

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...

2don MSN

AstraZeneca, BioNTech, GSK, Sanofi, Moderna, Novavax, Pfizer share prices: Why are vaccine stocks down?

S hares of global vaccine makers were muted on Tuesday as investors and analysts took a "wait and watch" approach after U.S.

3d

Beyfortus Output Tripled As Sanofi, AstraZeneca Scale Up For RSV Season

French drugmaker Sanofi SA (NASDAQ:SNY) on Monday said it is shipping Beyfortus (nirsevimab) starting in early Q3 to ensure ...

Sanofi starts shipping RSV drug early as rival nears market

Clesrovimab has been held up by MSD (known as Merck & Co in the US and Canada) as offering simpler dosing and better clinical ...

Fierce Pharma3d

Feeling RSV heat from Merck, Sanofi lays out early supply plans for Beyfortus

One day before the potential FDA approval of a rival respiratory syncytial virus (RSV) monoclonal antibody from Merck & Co., ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results